- Home
- APLS vs ACHC Comparison
APLS vs ACHC Comparison
Compare APLS & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- ACHC
- Stock Information
- Founded
- APLS 2009
- ACHC 2005
- Country
- APLS United States
- ACHC United States
- Employees
- APLS N/A
- ACHC N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- ACHC Medical Specialities
- Sector
- APLS Health Care
- ACHC Health Care
- Exchange
- APLS Nasdaq
- ACHC Nasdaq
- Market Cap
- APLS 2.2B
- ACHC 2.1B
- IPO Year
- APLS 2017
- ACHC N/A
- Fundamental
- Price
- APLS $16.93
- ACHC $22.64
- Analyst Decision
- APLS Buy
- ACHC Buy
- Analyst Count
- APLS 19
- ACHC 9
- Target Price
- APLS $37.50
- ACHC $47.94
- AVG Volume (30 Days)
- APLS 2.9M
- ACHC 2.4M
- Earning Date
- APLS 05-07-2025
- ACHC 05-12-2025
- Dividend Yield
- APLS N/A
- ACHC N/A
- EPS Growth
- APLS N/A
- ACHC N/A
- EPS
- APLS N/A
- ACHC 2.04
- Revenue
- APLS $775,839,000.00
- ACHC $3,156,417,000.00
- Revenue This Year
- APLS $1.54
- ACHC $7.86
- Revenue Next Year
- APLS $22.80
- ACHC $8.55
- P/E Ratio
- APLS N/A
- ACHC $11.10
- Revenue Growth
- APLS 48.04
- ACHC 5.48
- 52 Week Low
- APLS $16.10
- ACHC $20.36
- 52 Week High
- APLS $43.76
- ACHC $82.41
- Technical
- Relative Strength Index (RSI)
- APLS 41.44
- ACHC 40.69
- Support Level
- APLS $16.61
- ACHC $22.30
- Resistance Level
- APLS $17.48
- ACHC $23.58
- Average True Range (ATR)
- APLS 0.86
- ACHC 1.21
- MACD
- APLS 0.09
- ACHC -0.11
- Stochastic Oscillator
- APLS 28.47
- ACHC 7.59
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.